Altitude Sickness Prevention: What Every Athlete Needs to Know Before Going High

Altitude sickness prevention is not just a safety issue for mountaineers — it's a critical performance issue for any athlete training above 2,000 meters. Acute mountain sickness (AMS) is more common than most coaches and athletes expect: studies estimate 25–50% of people ascending rapidly to 2,500–3,000 meters experience some degree of AMS, and the rates climb steeply with elevation and ascent speed.

For athletes, AMS doesn't just cause discomfort — it disrupts sleep, impairs training adaptation, elevates cortisol, and can force a shortened or abandoned camp. Understanding how to prevent altitude sickness is as important as any other aspect of altitude training preparation.

What Is Altitude Sickness?

Altitude sickness encompasses a spectrum of conditions caused by acute hypoxia — insufficient oxygen delivery to tissues following rapid ascent to high elevation.

Acute Mountain Sickness (AMS) is the mild-to-moderate end of the spectrum. Symptoms typically appear 6–12 hours after arriving at altitude and include:

• Headache (the defining symptom)
• Fatigue and weakness
• Dizziness or lightheadedness
• Loss of appetite, nausea
• Difficulty sleeping

AMS is uncomfortable but self-limiting if altitude is maintained and further ascent is avoided. Most cases resolve within 2–3 days as acclimatization proceeds.

High-Altitude Cerebral Edema (HACE) is severe AMS with neurological involvement — fluid accumulation in the brain. Symptoms include confusion, loss of coordination (ataxia), and altered consciousness. HACE is a medical emergency requiring immediate descent and treatment.

High-Altitude Pulmonary Edema (HAPE) is fluid accumulation in the lungs, presenting as breathlessness at rest, cough (often pink-tinged), and extreme fatigue. HAPE is the most common cause of altitude-related death and requires immediate descent.

Athletes training at 2,000–3,000 meters are primarily at risk for AMS, though exceptional effort or individual susceptibility can increase HACE and HAPE risk even at moderate elevations.

Risk Factors for Altitude Sickness

Understanding your personal risk factors is the starting point for altitude sickness prevention.

Factors That Increase AMS Risk

Rate of ascent is the most controllable risk factor. Ascending to altitude within 24 hours (flying to a mountain town, for example) produces far higher AMS rates than a gradual ascent over several days. Research consistently shows that spending 1–2 nights at an intermediate elevation (e.g., 1,500–1,800 m) before reaching camp altitude significantly reduces AMS incidence.

Prior AMS history is the strongest predictor of future susceptibility. If you've experienced AMS before, your risk of recurrence at similar altitudes is substantially higher than the general population. This isn't a disqualifier for altitude training, but it demands proactive prevention.

Altitude of destination: AMS incidence rises steeply with elevation.

• 2,000–2,500 m: ~10–20% incidence with rapid ascent
• 2,500–3,000 m: ~25–40% incidence with rapid ascent
• 3,000–3,500 m: ~40–60% incidence with rapid ascent

Sleep altitude: Your sleeping altitude matters more than your peak daytime altitude. The body's acclimatization is largely governed by nighttime oxygen exposure — higher sleeping altitude means greater hypoxic stress and higher AMS risk.

Exertion on arrival: Strenuous exercise on day 1 at altitude is strongly associated with AMS development. The physiological stress of exercise compounds the hypoxic challenge, elevating AMS risk substantially.

Factors That Are NOT Reliable Predictors

Fitness level does not protect against AMS. This surprises most athletes. Elite aerobic capacity does not correlate with reduced AMS susceptibility — highly fit athletes develop AMS at the same rates as untrained individuals. Do not use your fitness as justification for aggressive ascent protocols.

Age: AMS susceptibility is relatively stable across adult age ranges, though some evidence suggests younger individuals (under 25) have slightly higher risk.

Sex: Men and women show similar AMS rates at comparable altitudes.

Science-Backed Prevention Strategies

1. Gradual Ascent (The Most Effective Strategy)

The single most effective altitude sickness prevention measure is a staged ascent. The general guideline:

Above 2,500 m, limit sleeping altitude gain to 300–500 meters per day, with a rest day every third day.

For athletes flying directly to their training destination (which often involves arriving at 2,000–2,500 m without staging), spending 1–2 nights at an intermediate elevation significantly reduces AMS risk. Even one night at 1,200–1,500 m before arrival at 2,500 m can meaningfully reduce symptoms.

Practical examples:

• Flying to Flagstaff, AZ (2,100 m): spend 1 night in Phoenix (~300 m) or drive up the day before to arrive in the afternoon and begin light activity
• Flying to Font Romeu, France (1,850 m): minimal staging needed for most athletes
• Flying to Quito, Ecuador (2,850 m) for a high-altitude camp: stage 1–2 nights at a mid-altitude destination

2. Acetazolamide (Diamox)

Acetazolamide is the only pharmacological AMS prevention strategy with strong clinical evidence. It is a carbonic anhydrase inhibitor that accelerates bicarbonate excretion by the kidneys, effectively mimicking the pH compensation that acclimatization normally takes days to produce.

Mechanism: By promoting bicarbonate excretion, acetazolamide allows more aggressive breathing (correcting the respiratory alkalosis that normally limits hyperventilation), improving oxygen saturation and accelerating acclimatization.

Dosing (per Wilderness Medical Society guidelines):

• Prophylactic: 125 mg twice daily, starting 24 hours before ascent and continuing for 48 hours at altitude
• Higher doses (250 mg twice daily) are used for higher elevations or prior AMS history

Side effects include frequent urination, tingling in extremities (paresthesias), and occasional taste disturbances with carbonated drinks. Rare but serious: sulfa drug allergy (acetazolamide is sulfa-based).

For athletes: Acetazolamide can alter acid-base balance in ways that may marginally affect high-intensity performance, though this effect is small and largely academic for the prophylactic doses used for AMS prevention. The performance impact of AMS itself far exceeds any pharmacological side effect.

Consult a physician before using acetazolamide. It is prescription-only in most countries.

3. Ibuprofen for AMS Prevention

A 2012 randomized controlled trial published in JAMA found that ibuprofen (600 mg three times daily) significantly reduced AMS incidence compared to placebo in trekkers ascending to 4,920 meters. The effect was comparable to acetazolamide in this study.

Mechanism is thought to involve reduction of cerebral vasodilation (a component of AMS headache pathophysiology) and anti-inflammatory effects.

For athletes: Ibuprofen at 400 mg taken at arrival and again at bedtime for the first 2–3 days is a practical, accessible prevention strategy that many athletes find preferable to acetazolamide. Note the standard cautions around NSAID use with strenuous exercise (kidney stress, GI issues with dehydration).

4. Pre-Acclimatization

Athletes with access to altitude tents or altitude simulation facilities can begin hypoxic exposure 2–3 weeks before arrival at altitude. This "pre-acclimatization" strategy reduces AMS incidence by initiating the acclimatization process before the camp begins.

Research by Savourey et al. and others shows that 2 weeks of intermittent normobaric hypoxia (3–5 hours/day at simulated 3,000–4,000 m) reduces AMS incidence and severity upon arrival at moderate altitude.

Pre-acclimatization also helps ensure athletes are physiologically primed for adaptation rather than spending the first week of a camp fighting AMS.

5. Hydration

Dehydration is a potent AMS amplifier. Altitude causes increased insensible water loss through respiration (cold, dry air accelerates respiratory water evaporation). Athletes at altitude lose an estimated 1–2 additional liters per day compared to sea level.

Prevention: Increase daily fluid intake by at least 750–1,000 mL above normal. Aim for pale yellow urine as a practical target. Avoid alcohol for the first 72 hours, as it impairs acclimatization and contributes to dehydration.

6. Avoid Exertion on Arrival Day

The combination of travel fatigue, dehydration, and immediate strenuous exercise is a reliable recipe for AMS. Arrival day should be a rest day or very light walking only, regardless of how good you feel.

The "climb high, sleep low" principle applies even when logistics are difficult: if you must be at altitude immediately, minimize exertional stress on day 1.

Recognizing and Responding to AMS

Despite prevention strategies, some athletes will develop AMS. Early recognition is critical because the window between AMS and the more dangerous HACE/HAPE is not always wide.

Lake Louise AMS Score (validated screening tool):

Score interpretation:

• 3–4: Mild AMS — no further ascent, rest, hydrate, observe
• 5–7: Moderate AMS — no further ascent, consider acetazolamide or descent, close monitoring
• ≥8, or any neurological symptoms (confusion, ataxia), or breathlessness at rest: Descend immediately

The decision to descend should always err toward caution. A 300–500 meter descent can dramatically improve symptoms within hours. Do not wait to see if you "feel better in the morning" if symptoms are escalating.

Key Prevention Protocol for Athletes

Summarizing the evidence into a practical pre-arrival and on-arrival protocol:

4–6 weeks before camp:

• Test serum ferritin (target ≥70 ng/mL)
• Begin pre-acclimatization if altitude tent is available (3–5 hours/day at simulated 2,500–3,500 m)

1–2 days before camp:

• Begin acetazolamide (125–250 mg twice daily) if using pharmacological prevention
• Arrive at intermediate elevation if logistically feasible

Arrival day:

• Rest only — no training
• Aggressive hydration (add 1L minimum to normal intake)
• Light eating even if appetite is low
• No alcohol

Days 1–3:

• Score AMS symptoms daily using Lake Louise Scale
• Train only at RPE ≤ 5/10
• Continue acetazolamide if using
• Monitor SpO2 with pulse oximeter if available; resting SpO2 <80% warrants physician consultation

Day 3+:

• If AMS-free, begin gradual reintroduction of training load
• If AMS score ≥5 or symptoms not improving: do not ascend, consider descent

Want a personalized altitude risk assessment and prevention checklist? Join the AltitudePerformanceLab email list to get the free pre-camp preparation guide used by serious endurance athletes.